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Aim: To assess cardiorenal outcomes by baseline urinary albumin-to-creatinine ratio
(UACR) and estimated glomerular filtration rate (eGFR) in the contemporary LEADER
cohort.
Materials and methods: LEADER was a multinational, double-blind trial. Patients with
type 2 diabetes and high cardiovascular (CV) risk were randomized 1:1 to the
glucagon-like peptide-1 analogue liraglutide (≤1.8 mg daily; n = 4668) or placebo
(n = 4672) plus standard care and followed for 3.5 to 5 years. Primary composite out-
comes were time to first non-fatal myocardial infarction, non-fatal stroke or CV
death. Post hoc Cox regression analyses of outcomes by baseline UACR and eGFR
subgroups were conducted with adjustment for baseline variables.
Results: In the LEADER population, 1598 (17.5%), 2917 (31.9%), 1200 (13.1%), 1611
(17.6%), 845 (9.2%) and 966 (10.6%) had UACR = 0, >0 to <15, 15 to <30, 30 to
<100, 100 to <300 and ≥300 mg/g, respectively. Increasing UACR and decreasing
eGFR were linked with higher risks of the primary outcome, heart failure hospitaliza-
tion, a composite renal outcome and death (P-values for the Cochran-Armitage test
for trends were all <.0001). Across UACR and eGFR subgroups, risks of cardiorenal
events and death were generally lower or similar with liraglutide versus placebo.
Conclusions: In a contemporary type 2 diabetes population, increasing baseline
UACR and declining eGFR were linked with higher risks of cardiorenal events and
death.
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1 | INTRODUCTION
The risk of cardiovascular (CV) events increases continuously with
increasing albuminuria, starting without a threshold within ranges of
normal values.1–5 The risk of CV events also increases with decreasing
estimated glomerular filtration rate (eGFR) below a threshold level of
~60-75 mL/min/1.73m2.1,5
To ensure appropriate monitoring and treatment, it is important
to understand the relationships between urinary albumin-to-
creatinine ratio (UACR) and eGFR and clinical outcomes in
contemporary populations receiving guideline-recommended, stan-
dard-of-care treatments. Recently completed CV outcomes trials of
glucose-lowering therapies provide the opportunity to assess these
relationships in populations with type 2 diabetes (T2D).
In the LEADER trial, liraglutide, a glucagon-like peptide-1 (GLP-1)
analogue, significantly reduced the risk of major adverse CV events
(MACE) versus placebo in patients with T2D and high CV risk.6 This
effect was preserved in patients with elevated albuminuria and/or low
eGFR.7 In the overall LEADER population, patients who received
liraglutide also experienced lower rates of a prespecified secondary
composite renal outcome, a smaller increase in UACR and a slightly
slower eGFR decline than patients who received placebo.8
This analysis assessed cardiorenal outcomes and death in the con-
temporary LEADER cohort by baseline UACR and eGFR subgroups.
We hypothesized that the risk of cardiorenal events would increase
with increasing baseline UACR and decreasing baseline eGFR in the
overall LEADER population. We also analysed treatment effects of
liraglutide according to multiple UACR and eGFR subgroups.
2 | MATERIALS AND METHODS
2.1 | Study design
The LEADER trial (https://clinicaltrials.gov/ct2/show/NCT01179048)
design has been detailed elsewhere.6 Briefly, 410 sites in 32 countries
participated in this randomized, double-blind, placebo-controlled trial.
The trial included patients with T2D (HbA1c ≥7.0%) aged 50 years or
older with either established CV disease or chronic kidney disease
(CKD), or aged 60 years or older with at least one CV risk factor.
LEADER was designed to recruit 440 or more patients with moderate
renal impairment (eGFR 30-59 mL/min/1.73m2) and 220 patients
with severe renal impairment (eGFR <30 mL/min/1.73m2). Between
September 2010 and April 2012, patients were randomized 1:1 to
receive subcutaneous liraglutide daily (1.8 mg/day or the maximum
tolerated dose ≤1.8 mg/day [Novo Nordisk A/S, Bagsværd, Denmark])
or equivalent placebo, both in addition to standard care. The treat-
ment period was 3.5-5 years, with a 30-day follow-up period. A global
expert panel developed treatment guidelines to encourage investiga-
tors to manage participants' blood glucose, blood pressure and lipid
levels, and to guide concomitant therapy. The trial was conducted in
accordance with the Declaration of Helsinki. The protocol6 was
reviewed and approved by the institutional review board or ethics
committee at each participating centre, and all patients provided writ-
ten informed consent.6
We analysed cardiorenal outcomes and death by baseline UACR
and eGFR subgroups. In the analyses by UACR, the following sub-
groups were evaluated: urinary albumin less than the lower limit of
quantification (LLoQ) of 3.0 mg/L (referred to as UACR 0); urinary
albumin ≥LLoQ with UACR <15 mg/g (referred to as UACR >0 to
<15 mg/g); UACR 15 to <30; UACR 30 to <100; UACR 100 to <300;
and UACR ≥300 mg/g. In the analyses by eGFR, the following sub-
groups were evaluated, based on baseline eGFR calculated using the
Modification of Diet in Renal Disease study equation: ≥90; 60 to <90;
45 to <60; 30 to <45; and <30 mL/min/1.73m2.
2.2 | Study outcomes and laboratory assessments
The primary composite MACE outcome was time to first occurrence of
non-fatal myocardial infarction (MI), non-fatal stroke or CV death. Key
secondary outcomes included time to first occurrence of an expanded
composite CV outcome (expanded MACE; MACE plus coronary revas-
cularization or hospitalization for unstable angina pectoris or heart
failure [HF]), time to all-cause death, time to individual components of
expanded MACE and time to a composite renal outcome (new-onset
persistent macroalbuminuria [UACR ≥300mg/g], persistent doubling of
serum creatinine and eGFR ≤45 mL/min/1.73m2, the need for continu-
ous renal replacement therapy [in the absence of an acute reversible
cause; end-stage renal disease {ESRD}], or death from renal disease).8 An
external, independent, blinded event adjudication committee adjudicated
these outcomes. We analysed the risk of MACE, expanded MACE, indi-
vidual components of MACE and expanded MACE, all-cause death and
the renal composite outcome by baseline UACR and eGFR subgroups.
For the analyses by baseline UACR subgroups, the component
of new-onset persistent macroalbuminuria was excluded from the
renal composite outcome because some patients had pre-existing
macroalbuminuria at baseline (Table S1), and because this modified
renal outcome might be considered stronger and more clinically relevant.
The main analyses by baseline eGFR subgroups included new-onset per-
sistent macroalbuminuria as part of the renal composite outcome, but
additional analyses were conducted that excluded this component.
UACR was assessed at randomization and then annually. Serum cre-
atinine was measured at screening, randomization, month 6, month 12
and then annually. Laboratory analyses were performed centrally (ICON
Laboratory Services/Central Laboratories; Dublin, Ireland; New York,
USA; Tianjin, China; Loyang, Singapore; Bangalore, India). Urinary albu-
min levels were assessed using immunoprecipitation (Roche-Hitachi).8
Urinary and serum creatinine levels were measured enzymatically, cali-
brated to isotope dilution mass spectrometry values (Roche-Hitachi).8
2.3 | Statistical analyses
Exploratory analyses of treatment effects on the primary and second-
ary outcomes by renal function subgroups were prespecified in the
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protocol,6 but the present subgroup analyses were post hoc. Data for
patients taking liraglutide or placebo were both pooled and analysed
separately.
All patients who underwent randomization were included from
the time of randomization until the end of their follow-up or death.
Urinary albumin or creatinine measurements less than the LLoQ
were imputed using a value of 0.5 × LLoQ; those greater than the
higher limit of quantification (HLoQ; n = 24 patients) were imputed
using the HLoQ value. All patients with urinary albumin less than the
LLoQ were included in a separate subgroup (UACR 0).
Time to first event was estimated using a Cox regression model.
In the pooled analyses and in the analyses by treatment arm in the
overall population, the Cox regression model was adjusted for treat-
ment arm. Analyses by baseline UACR subgroups were performed
with adjustment for important baseline variables, including age, sex,
smoking status, diabetes duration, HbA1c, systolic and diastolic blood
pressure, low-density lipoprotein cholesterol, glucose-lowering medi-
cation, prior MI or stroke, geographic region and eGFR. Similar time-
to-event analyses were conducted for the baseline eGFR subgroups,
but with adjustment for UACR instead of eGFR.
Tests for trends according to the UACR and eGFR subgroups
pooled across treatment arms were performed using the Cochran-
Armitage test. Tests for heterogeneity of treatment effects across
UACR and eGFR subgroups were also performed, providing P-values
for interaction (P-interaction). Statistical significance was defined
as P <.05.
Numbers of patients who would need to be treated (NNT) with
liraglutide to prevent one additional MACE, composite renal outcome,
CV death, all-cause death or hospitalization for HF at 3 years of fol-
low-up were calculated for the UACR and eGFR subgroups, based on
methods described previously.9
In the statistical analyses evaluating time to first MACE by combi-
nations of both UACR and eGFR subgroups, P-values were adjusted
for multiplicity using Bonferroni correction. No further corrections for
multiplicity were performed because of the post hoc and exploratory
nature of these analyses.
3 | RESULTS
3.1 | Baseline characteristics
The patient disposition and baseline characteristics for the LEADER
trial population (n = 9340 randomized: liraglutide, n = 4668; placebo,
n = 4672) have been published previously.6 The distribution of UACR
and eGFR subgroups at baseline is shown in Figure S1, Tables S1
and S2.
With increasing baseline UACR, the proportion of males, HbA1c,
diabetes duration and blood pressure tended to increase, while eGFR
tended to decrease (Table S1).
With decreasing baseline eGFR, diabetes duration and UACR
tended to increase, while male prevalence and diastolic blood pressure
tended to decrease (Table S2).
3.2 | Cardiorenal outcomes and death by
baseline UACR
Risks of MACE, expanded MACE, individual components of MACE,
coronary revascularization, hospitalization for HF, the composite renal
outcome and all-cause death increased with increasing baseline UACR
(P-value for Cochran-Armitage test for trend <.0001 for all outcomes
shown in Figure 1A and Figure S2A, except for coronary revasculariza-
tion [P < .05] and hospitalization for unstable angina pectoris [P = .20]).
There were significantly higher risks of expanded MACE, hospitaliza-
tion for HF and all-cause death among all subgroups with UACR
≥30 mg/g versus the albumin less than LLoQ subgroup (UACR 0).
Among patients in the UACR 15 to <30 mg/g subgroup, although
there were numerically higher risks of hospitalization for HF and all-
cause death (Figure 1A) versus UACR 0, these were not statistically
significant (P = .10 and P = .09, respectively).
3.3 | Cardiorenal outcomes and death by baseline
UACR: effect of randomized treatment arm
Risks of cardiorenal events and death were generally lower or similar
with liraglutide versus placebo across UACR subgroups (Figure 2A
and Figure S3A). No statistically significant interaction was detected
between baseline UACR subgroup and randomized treatment for
most outcomes (Figure 2A and Figure S3A). The exception to that was
for HF hospitalization. Risk for HF hospitalization with liraglutide ver-
sus placebo differed across UACR subgroups from 0.42 (95% CI 0.23;
0.78; P = .006) in the 15 to <30 mg/g subgroup to 1.64 (95% CI 1.09;
2.46; P = .02) in the UACR ≥300mg/g subgroup (P interaction = .0017;
Figure 2A).
At 3 years of follow-up, absolute risk reductions in the composite
renal outcome, CV death and all-cause death with liraglutide versus
placebo were numerically greatest in the subgroup with baseline
UACR ≥300mg/g (Table 1). The corresponding NNT with liraglutide to
prevent one additional composite renal outcome, CV death or all-
cause death were lowest in those with baseline UACR ≥300 mg/g
(Table 1). Again, the exception to this pattern was HF hospitalization,
for which the numerically greatest absolute risk reductions were
observed in the subgroup with baseline UACR 15 to >30 mg/g, with
an increased risk in the subgroup with baseline UACR ≥300 mg/g
(absolute risk reduction: –4.0 [95% CI –7.5; 0.5]).
3.4 | Cardiorenal outcomes and death by
baseline eGFR
Risks of MACE, expanded MACE, non-fatal MI, hospitalization for HF,
the composite renal outcome, CV death and all-cause death increased
with declining baseline eGFR (P-value for Cochran-Armitage test for
trend <.0001 for the outcomes in Figure 1B and Figure S2B, except
for non-fatal MI [P <.01], non-fatal stroke [P = .11], coronary revascu-
larization [P = .15] and hospitalization for unstable angina pectoris
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[P = .13]). There were significantly higher risks of MACE, expanded
MACE, hospitalization for HF, the composite renal outcome, CV death
and all-cause death among all subgroups with eGFR <60 mL/min/
1.73m2 versus the eGFR ≥90 mL/min/1.73m2 subgroup (Figure 1B
and Figure S2B). Risks of hospitalization for HF, the composite renal
outcome, CV death and all-cause death were higher among all sub-
groups with eGFR <90 mL/min/1.73m2 versus the eGFR ≥90 mL/
min/1.73m2 subgroup (Figure 1B and Figure S2B).
Additional analyses by eGFR subgroup that excluded new-onset
persistent macroalbuminuria from the renal composite outcome (Fig-
ure S4A) provided qualitatively similar results to the main analyses of
the renal outcome (Figure 1B), but decreasing eGFR was linked with
even higher renal risk.
3.5 | Cardiorenal outcomes and death by baseline
eGFR: effect of randomized treatment arm
Risks of cardiorenal events and death were lower or similar with
liraglutide versus placebo across eGFR subgroups (Figure 2B and
Figure S3B). No statistically significant interaction was detected
between baseline eGFR subgroup and randomized treatment for most
outcomes (Figure 2B and Figure S3B). At 3 years of follow-up, abso-
lute risk reductions in first MACE, the composite renal outcome, all-
cause death and hospitalization for HF with liraglutide versus placebo
were numerically greatest in the subgroup with baseline eGFR 30 to
<45 mL/min/1.73m2 (Table 2). The corresponding NNT to prevent
one additional MACE, composite renal outcome, all-cause death or
0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00 64.00
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F IGURE 1 Risks of composite CV outcomes, death, renal outcome and hospitalization for heart failure according to (A) baseline UACR and
(B) baseline eGFR, adjusted for baseline variables. †UACR 0 was assigned as the reference group for HRs. ‡Excludes new-onset persistent
macroalbuminuria. §eGFR ≥90 mL/min/1.73m2 was assigned as the reference group for HRs. Data pooled for patients taking liraglutide or
placebo. See methods for adjusted baseline variables and outcome components; P-trend calculated using the Cochran-Armitage test for trends.
CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; hosp. for HF, hospitalization for heart failure; HR, hazard
ratio; MACE, major adverse cardiovascular events; n, number of patients with an event; UACR, urinary albumin-to-creatinine ratio; UACR 0,
urinary albumin < lower limit of quantification
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hospitalization for HF were lowest in those with baseline eGFR 30 to
<45 mL/min/1.73m2 (Table 2). For CV death, the highest absolute risk
reductions and lowest NNT were observed in those with baseline
eGFR <45 mL/min/1.73m2 (Table 2).
Additional analyses by eGFR subgroup that excluded new-onset
persistent macroalbuminuria from the renal composite outcome
(Figure S4B) provided broadly similar results to the main subgroup
analyses of treatment effects on the renal outcome (Figure 2B). How-
ever, the reduction in risk with liraglutide versus placebo in the sub-
group with eGFR 60 to <90 mL/min/1.73m2 was no longer
statistically significant.
3.6 | MACE by both baseline UACR and
baseline eGFR
Rates of MACE generally increased with increasing baseline UACR
and decreasing baseline eGFR (Figure 3), but this pattern was incon-
sistent. The interaction between UACR and eGFR for MACE was not
statistically significant (P = .45). It should be noted that some of the
relevant subgroups were small, particularly at the lowest baseline
eGFR levels (<30 mL/min/1.73m2; Table S1), where recruitment was
limited by trial design. The outlying rate of MACE in the subgroup
with UACR 0 and eGFR <30 mL/min/1.73m2, which only included 10
patients, was based on four events.
4 | DISCUSSION
Based on pooled data for both treatment arms, increasing baseline
UACR and declining baseline eGFR were each linked with higher risks
of several adverse CV outcomes, a composite renal outcome and
death in LEADER participants with T2D and high CV risk. Thus, the
hypothesis that the risk of cardiorenal events would increase with
increasing baseline UACR and decreasing eGFR was supported. We
observed changes towards higher risks of hospitalization for HF and
all-cause death even among patients with UACR values in the upper
normo-albuminuric range (UACR 15 to <30 mg/g vs. UACR 0). Risks
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F IGURE 1 (Continued)
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of cardiorenal events and death were generally lower or similar with
liraglutide versus placebo across UACR and eGFR subgroups. In ana-
lyses by UACR, absolute reductions in the risk of a composite renal
outcome, CV or all-cause death with liraglutide were numerically
greatest in those with baseline UACR ≥300 mg/g, with lower NNT in
this subgroup than in those with lower baseline UACR at 3 years. This
was probably because risks of these outcomes were most elevated in
this subgroup versus UACR 0.
Results of our pooled analyses are in line with other
findings.1–3,5,10–13 Our findings confirm that elevated albuminuria and
reduced renal function are linked with cardiorenal events and death in
patients with T2D.5,11,12 They also add to the existing literature,
showing that these associations exist in a contemporary cohort with
T2D, in which the great majority of participants were receiving con-
comitant CV and glucose-lowering medications, and half were ran-
domized to treatment with a GLP-1 receptor agonist (GLP-1RA).6
Overall, 51% of LEADER participants were receiving angiotensin con-
verting enzyme (ACE) inhibitors and 32% were receiving angiotensin
receptor blockers (ARBs) at baseline6; these medications are consid-
ered standard of care treatments for diabetes-related nephropathy
and many other forms of CKD.14
In patients with T2D and normoalbuminuria, intervention with
certain CV or glucose-lowering medications may reduce the risk of
developing microalbuminuria.8,15–19 For example, treatment with ACE
0.13 0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00 64.00
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F IGURE 2 Risks of composite CV outcomes, death, renal outcome and hospitalization for heart failure according to (A) baseline UACR and
treatment group and (B) baseline eGFR and treatment group, adjusted for baseline variables. Placebo was assigned as the reference group for
HRs. †Two-sided P-value for superiority. ‡Excludes new-onset persistent macroalbuminuria. See methods for adjusted baseline variables and
outcome components. Analyses by baseline UACR included 9137 patients (liraglutide, N = 4578; placebo, N = 4559). CI, confidence interval; CV,
cardiovascular; eGFR, estimated glomerular filtration rate; hosp. for HF, hospitalization for heart failure; HR, hazard ratio; MACE, major adverse
cardiovascular events; N, number of patients in subgroup; n, number of patients with an event; UACR, urinary albumin-to-creatinine ratio; UACR
0, urinary albumin < lower limit of quantification
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inhibitors or ARBs is superior to placebo for preventing the develop-
ment of microalbuminuria.15 However, ACE inhibitor or ARB therapy
is not recommended for primary CKD prevention in patients with dia-
betes who have normal blood pressure, UACR <30 mg/g and normal
eGFR.20 There is a need for other treatment options to prevent new-
onset microalbuminuria in patients without hypertension or eGFR
<60 mL/min/1.73m2.
There is a suggestion that reducing albuminuria may decrease the
risk of cardiorenal events and death.21–23 Glucose-lowering medica-
tions are available that can reduce albuminuria in patients with T2D.
In a randomized, crossover trial involving patients with T2D and per-
sistent albuminuria, liraglutide reduced the 24-hour urinary albumin
excretion rate by 32% versus placebo.24 In LEADER, there was a
smaller increase in albuminuria at 36 months in the liraglutide group
than in the placebo group, yielding a 17% lower UACR in favour of
liraglutide. This effect was independent of baseline albuminuria.8
Fewer patients in the liraglutide group than in the placebo group
experienced new-onset microalbuminuria or new-onset persistent
macroalbuminuria.8 Other GLP-1RAs (e.g. semaglutide, lixisenatide
and dulaglutide) have also been linked with improvements in UACR
versus comparators in patients with T2D.25–27 Preclinical data suggest
that the renoprotective action of GLP-1RAs may involve an anti-
inflammatory effect, reduced oxidative stress and/or modulation of
renin-angiotensin-aldosterone system signalling.28–30 A dedicated
renal outcomes trial initiated in June 2019 will assess the effect of
semaglutide versus placebo on the progression of renal impairment in
patients with T2D and CKD, with relative change in UACR, time to
first MACE and time to all-cause death as secondary endpoints
(FLOW; ClinicalTrials.gov: NCT03819153).31
Other glucose-lowering medications reported to reduce UACR
versus placebo in patients with T2D include sodium-glucose co-trans-
porter-2 (SGLT-2) inhibitors (e.g. empagliflozin, canagliflozin and
dapagliflozin) and, to a much lesser degree, dipeptidyl peptidase-4
inhibitors (e.g. sitagliptin, saxagliptin and linagliptin).16,17,32–35
eGFR
0.130.06 0.25 0.50 1.00 2.00 4.00 8.00 16.00 32.00 64.00
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F IGURE 2 (Continued)
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Recently, a dedicated renal outcomes trial, CREDENCE, showed a
lower risk of kidney failure and CV events with the SGLT-2 inhibitor
canagliflozin versus placebo in patients with T2D and kidney dis-
ease.36 Among patients with T2D who have established atheroscle-
rotic CV or kidney disease, a SGLT-2 inhibitor or GLP-1RA with
proven CV benefit is recommended.37 The decision to treat high-risk
patients with a SGLT-2 inhibitor or GLP-1RA to reduce MACE, hospi-
talization for HF, CV death or CKD progression should be considered
independently of baseline HbA1c or HbA1c target.38
The combination of high albuminuria and reduced eGFR may be
linked with even higher risks of cardiorenal events than reduced eGFR
alone.5 We did not identify a statistically significant interaction
between UACR and eGFR for MACE, but a strong synergistic interac-
tion between the two has been identified previously for progression
to ESRD and mortality in patients with diabetes.39
The current analysis suggested that while in lower baseline UACR
(15 to <100 mg/g) liraglutide reduced the risk for HF hospitalization,
in patients with baseline UACR of more than 300 mg/g the risk was




Number of patients with
an event during the trial ARR (95% CI) NNT (95% CI) NNH
First MACE 0 174 1.1 (−1.4; 3.5) 94 (29; ∞) —
>0 to <15 mg/g 328 −0.4 (−2.3; 1.6) — 284
15 to <30 mg/g 151 2.7 (−0.3; 5.7) 37 (18, ∞) —
30 to <100 mg/g 232 1.3 (−1.5; 4.0) 77 (25; ∞) —
100 to <300 mg/g 151 4.8 (0.6; 8.9) 21 (11; 162) —
≥300 mg/g 232 1.8 (−2.9; 6.6) 55 (15; ∞) —
CV death 0 65 0.4 (−0.9; 1.7) 245 (59; ∞) —
>0 to <15 mg/g 91 0.2 (−0.7; 1.2) 447 (84; ∞) —
15 to <30 mg/g 61 1.3 (−0.5; 3.1) 78 (32; ∞) —
30 to <100 mg/g 94 0.7 (−1.0; 2.5) 136 (40; ∞) —
100 to <300 mg/g 59 1.7 (−1.0; 4.4) 60 (23; ∞) —
≥300 mg/g 114 3.9 (0.5; 7.2) 26 (14; 210) —
All-cause death 0 95 −0.4 (−1.9; 1.1) — 246
>0 to <15 mg/g 174 0.5 (−0.7; 1.7) 201 (58; ∞) —
15 to <30 mg/g 101 0.9 (−1.3; 3.2) 107 (32; ∞) —
30 to <100 mg/g 157 1.5 (−0.7; 3.6) 68 (28; ∞) —
100 to <300 mg/g 105 1.6 (−1.7; 4.9) 63 (21; ∞) —
≥300 mg/g 175 3.0 (−0.8; 6.9) 33 (15; ∞) —
Renal outcomea 0 11 0.2 (−0.3; 0.8) 412 (128; ∞) —
>0 to <15 mg/g 14 0.0 (−0.2; 0.2) 16 474 (440; ∞) —
15 to <30 mg/g 7 −0.1 (−0.7; 0.5) — 1004
30 to <100 mg/g 25 0.2 (−0.5; 0.9) 446 (106; ∞) —
100 to <300 mg/g 16 0.0 (−1.3; 1.3) 9954 (76; ∞) —
≥300 mg/g 164 0.8 (−3.2; 4.8) 130 (21; ∞) —
Hospitalization for heart failure 0 43 0.1 (−1.1; 1.4) 949 (74; ∞) —
>0 to <15 mg/g 107 0.1 (−1.0; 1.3) 708 (80; ∞) —
15 to <30 mg/g 48 2.5 (0.7; 4.3) 39 (23; 136) —
30 to <100 mg/g 90 2.1 (0.4; 3.8) 49 (27; 282) —
100 to <300 mg/g 69 0.2 (−2.8; 3.1) 573 (32; ∞) —
≥300 mg/g 97 −4.0 (−7.5; 0.5) — 25
aPersistent doubling of serum creatinine and eGFR ≤45 mL/min/1.73m2, the need for continuous renal replacement therapy (in the absence of an acute
reversible cause; ESRD) or death from renal disease. NNT presented where the treatment difference favoured liraglutide; NNH presented where the treat-
ment difference favoured placebo. CIs were calculated on the risk difference scale and the reciprocals were then generated. The infinity notation has been
used where the CI contains zero or negative values. No 95% CIs are available for NNH (negative NNT).
Abbreviations: ARR, absolute risk reduction; CI, confidence interval; CV, cardiovascular; ESRD, end-stage renal disease; MACE, major adverse cardiovascu-
lar events; NNH, numbers needed to harm; NNT, numbers needed to treat; UACR, urinary albumin-to-creatinine ratio; UACR 0, urinary albumin < lower
limit of quantification.
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increased (P-value for interaction = .0017). However, the number of
events in this subgroup analysis was small and no correction for multi-
ple testing was completed on this outcome. In addition, these results
may be impacted by survival bias because liraglutide was associated
with fewer deaths than placebo in patients with a baseline UACR of
more than 300 mg/g. A specifically designed trial that tested the
effect of liraglutide on patients with advanced HF and reduced left
ventricular ejection fraction showed no specific effect of liraglutide in
this population.40 Similarly, a post hoc analysis focusing on patients
with HF in LEADER showed the suitability for liraglutide to be used in
patients with T2D and with or without HF.41 Regular (≥1/year) assess-
ment of both UACR and eGFR is recommended in all patients with
T2D.20,42 Our findings support this recommendation and reinforce
the importance of conserving renal function, where possible, in
patients with T2D and high CV risk.
The present study has limitations. First, the exploratory analyses
had limited power to assess the relationship between UACR and/or
eGFR subgroups, treatment and cardiorenal outcomes or death. Some
of the relevant subgroups were small. Second, performing multiple
statistical comparisons, as in this study, can increase the likelihood of
obtaining a spurious finding. Corrections for multiplicity were only
performed for statistical analyses evaluating combinations of both
UACR and eGFR subgroups. Additionally, LEADER was conducted in
patients with T2D at high risk of CV events, which may limit the gen-
eralizability of these findings to broader populations. Strengths of the
current analysis include its basis on a large, contemporary trial popula-
tion, with a median follow-up of 3.8 years and independent adjudica-
tion of events.
In conclusion, our findings highlight the importance of albumin-
uria and low eGFR as risk markers in patients with T2D and high CV
TABLE 2 Absolute risk reductions and numbers of patients needed to treat or harm by eGFR subgroups at 3 years of follow-up
Outcome
eGFR subgroup at baseline
(mL/min/1.73m2)
Number of patients with
an event during the trial ARR (95% CI) NNT (95% CI) NNH
First MACE ≥90 375 1.1 (−0.7; 2.9) 92 (35; ∞) —
60 to <90 532 0.1 (−1.6; 1.9) 868 (54; ∞) —
45 to <60 208 5.1 (1.7; 8.5) 20 (12; 58) —
30 to <45 136 6.5 (1.0; 11.9) 15 (8; 97) —
<30 51 2.0 (−8.1; 12.2) 49 (8; ∞) —
CV death ≥90 110 0.8 (−0.1; 1.7) 119 (58; ∞) —
60 to <90 198 0.3 (−0.7; 1.3) 337 (75; ∞) —
45 to <60 84 1.5 (−0.5; 3.5) 67 (28; ∞) —
30 to <45 77 4.3 (0.2; 8.5) 23 (12; 496) —
<30 28 5.8 (−2.4; 13.9) 17 (7; ∞) —
All-cause death ≥90 179 1.2 (0.1; 2.3) 85 (44; 1230) —
60 to <90 327 −0.0 (−1.3; 1.2) — 3861
45 to <60 148 1.9 (−0.7; 4.4) 54 (23; ∞) —
30 to <45 121 5.8 (1.2; 10.3) 17 (10; 87) —
<30 53 3.8 (−5.8; 13.5) 26 (7; ∞) —
Renal outcomea ≥90 22 0.1 (−0.2; 0.5) 699 (206; ∞) —
60 to <90 50 0.0 (−0.3; 0.4) 2759 (248; ∞) —
45 to <60 43 1.1 (−0.6; 2.8) 91 (36; ∞) —
30 to <45 62 2.3 (−1.5; 6.2) 43 (16; ∞) —
<30 66 1.0 (−10.4; 12.4) 102 (8; ∞) —
Hospitalization for heart failure ≥90 104 0.3 (−0.7; 1.2) 382 (84; ∞) —
60 to <90 178 0.0 (−1.1; 1.1) — —
45 to <60 87 2.7 (0.4; 4.9) 37 (20; 235) —
30 to <45 72 3.7 (−0.3; 7.6) 27 (13; ∞) —
<30 25 −4.3 (−10.8; 2.3) — 24
aPersistent doubling of serum creatinine and eGFR ≤45 mL/min/1.73m2, the need for continuous renal replacement therapy (in the absence of an acute
reversible cause; ESRD) or death from renal disease. NNT presented where the treatment difference favoured liraglutide; NNH presented where the treat-
ment difference favoured placebo. CIs were calculated on the risk difference scale and the reciprocals were then generated. The infinity notation has been
used where the CI contains zero or negative values. No 95% CIs are available for NNH (negative NNT).
Abbreviations: ARR, absolute risk reduction; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal
disease; MACE, major adverse cardiovascular events; NNH, numbers needed to harm; NNT, numbers needed to treat.
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risk. With regular assessment and early intervention, these variables
may be modifiable. Insights from this analysis are particularly relevant
given that CV and glucose-lowering medications that reduce albumin-
uria and/or eGFR decline have been identified, including liraglutide
and others. Further studies are required to explore mechanisms
underlying the effects of glucose-lowering therapies on albuminuria
and eGFR. Additionally, more outcomes trials with primary renal end-
points are required to increase understanding of the relative impact of
these treatments on cardiorenal outcomes and survival.
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F IGURE 3 Rates of MACE by baseline UACR and eGFR subgroups in the pooled analyses. *P < .05; **P < .01; ***P < .0001; all vs. UACR 0
with eGFR ≥90 mL/min/1.73m2. P-values are Bonferroni-adjusted. eGFR is presented in mL/min/1.73m2. Some of the relevant subgroups were
small, particularly at the lowest baseline eGFR levels (<30 mL/min/1.73m2), where recruitment was limited by trial design. The rate of MACE in
the subgroup with UACR 0 and eGFR <30 mL/min/1.73m2 was 12 events/100 PYO. The UACR 0 and eGFR <30 mL/min/1.73m2 subgroup only
included 10 patients and this outlying rate of MACE, which is not shown in the bar chart, was based on four events (n = 4 patients with first
MACE). eGFR, estimated glomerular filtration rate; MACE, major adverse cardiovascular events; PYO, patient-years of observation; UACR, urinary
albumin-to-creatinine ratio; UACR 0, urinary albumin < lower limit of quantification
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